IP Library › Granted Patent US 9,573,995
Granted Patent B2
US 9,573,995 · App. 14/795,007 · Granted Feb 21, 2017

Compositions and methods for growth factor modulation

Inventors: Thomas Schurpf (Cambridge, MA); Nagesh K. Mahanthappa (Cambridge, MA); Michelle Marie Straub (Brighton, MA)
Assignee: SCHOLAR ROCK, INC.
C07K16/22C07K14/495C07K16/005C07K16/2863C12N15/1037A61K38/00C07K2317/21C07K2317/24C07K2317/31C07K2317/565C07K2317/76C07K2317/92C07K2317/94G01N2333/71
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,573,995
App. No.
14/795,007
Granted
Feb 21, 2017
Kind
B2
Abstract

Provided herein are proteins, antibodies, assays and methods useful for modulating growth factor levels and/or activities. In some embodiments, such growth factors are members of the TGF-β superfamily of proteins.

Claims (13)

1. An antibody that binds to a protein complex, said protein complex comprising:

a. glycoprotein-A repetitions predominant protein (GARP) comprising the amino acid sequence of SEQ ID NO: 159, and

b. a growth factor prodomain complex (GPC) comprising human TGF-β1 growth factor and human TGF-β1 LAP;

wherein said antibody binds a GARP epitope of the protein complex, but does not bind free GARP.

2. The antibody of claim 1 , wherein said antibody is a TGF-β1 inhibiting antibody.

3. The inhibiting antibody of claim 2 , wherein said inhibiting antibody is a humanized antibody.

4. The inhibiting antibody of claim 2 , wherein said inhibiting antibody is a monoclonal antibody.

5. The inhibiting antibody of claim 2 , wherein said inhibiting antibody is a multispecific antibody.

6. The multispecific antibody of claim 5 comprising a bispecific antibody.

7. The inhibiting antibody of claim 2 , wherein said inhibiting antibody is an antibody fragment.

8. The inhibiting antibody of claim 7 , wherein said antibody fragment is selected from the group consisting of a Fab, a Fab′, a F(ab′) 2 , a Fv fragment, a diabody, a linear antibody, and a single-chain antibody molecule.

9. The inhibiting antibody of claim 2 comprising an antibody mimetic.

10. The inhibiting antibody of claim 9 , wherein the antibody mimetic is selected from the group consisting of a monobody, an affibody, an affilin, an affitin, an anticalin, an avimer, a centyrin, a darpin, and a fynomer.

Assignments (2)
SECURITY INTEREST Recorded Mar 3, 2026
From: SCHOLAR ROCK, INC.
To: LSI FINANCING LLC, AS ADMINISTRATIVE AGENT
Reel/Frame 075015/0854 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 3, 2015
From: SCHURPF, THOMAS; MAHANTHAPPA, NAGESH K.; STRAUB, MICHELLE MARIE
To: SCHOLAR ROCK, INC.
Reel/Frame 037202/0290 →
Continuity (5)
Continuation PCTUS2014036933 · May 6, 2014
Provisional Application 61819840 · May 6, 2013
Provisional Application 61823552 · May 15, 2013
Provisional Application 61900438 · Nov 6, 2013
Related Publication 20150361175A1 · Dec 17, 2015